Hi, I am Pitchai Balakumar, My LiveDNA is 91.3634
 
   
  Home  
 
 
 
Dr. Pitchai Balakumar
 
 
Institute: Rajendra Institute of Technology and Sciences, India
 
Area of Interest: Cardiovascular Pharmacology
  •   Cardiac Hypertrophy and Heart Failure
  •   Myocardial Ischemia-Reperfusion Injury
  •   Myocardial Preconditioning and Postconditioning
  •   Vascular Endothelial Physiology and Pathophysiology
 
URL: http://livedna.org/91.3634
 
My SELECTED Publications
Arora, M.K., K. Reddy and P. Balakumar, 2010. The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy. Eur. J. Pharmacol., 636: 137-144.
CrossRef  |  PubMed  |  Direct Link  |  
Asockson, C., V. Ganesan, L. Anuradha, N.P. Ashokkumar, P. Balakumar and V.G. Geetha, 2001. Hepatoprotective activity of punica granatum. Indian Drugs, 38: 183-186.
Balakumar, P, A. Rohilla and N. Mahadevan, 2011. Pleiotropic actions of fenofibrate on the heart. Pharmacol. Res., 63: 8-12.
PubMed  |  
Balakumar, P, M.K. Arora, S.S. Ganti, J. Reddy and M. Singh, 2009. Recent advances inpharmacotherapy for diabetic nephropathy: Current perspectives and future directions. Pharmacol. Res., 60: 24-32.
PubMed  |  
Balakumar, P. and G. Jagadeesh, 2010. Cardiovascular and renal pathological implications of prorenin, renin and the (pro)renin receptor: Promising young players from the Old renin-angiotensin-aldosterone system. J. Cardiovascular Pharmacol., 56: 570-579.
Balakumar, P. and G. Jagadeesh, 2010. Multifarious molecular signaling cascades of cardiac hypertrophy: Can the muddy waters be cleared?. Pharmacol. Res., 62: 365-383.
PubMed  |  
Balakumar, P. and G. Jagadeesh, 2011. Potential cross-talk between (pro)renin receptors and Wnt/frizzled receptors in cardiovascular and renal disorders. Hypertension Res., 10.1038/hr.2011.113.
CrossRef  |  PubMed  |  
Balakumar, P. and J. Kaur, 2009. Arsenic exposure and cardiovascular disorders: An overview. Cardiovasc. Toxicol., 9: 169-176.
CrossRef  |  
Balakumar, P. and J. Kaur, 2009. Is nicotine a key player or spectator in the induction and progression of cardiovascular disorders? Pharmacol. Res., 60: 361-368.
PubMed  |  
Balakumar, P. and M. Singh, 2005. The possible role of TNF-α in physiological and pathophysiological cardiac hypertrophy in rats. Ira. J. Pharmacol. Ther., 4: 138-142.
Balakumar, P. and M. Singh, 2006. Anti-TNF-α therapy in heart failure: Future directions. Basic Clin. Pharmacol. Toxicol., 99: 391-397.
Balakumar, P. and M. Singh, 2006. Differential role of rho-kinase in pathological and physiological cardiac hypertrophy in rats. Pharmacology, 78: 91-97.
Direct Link  |  
Balakumar, P. and M. Singh, 2006. Emerging drug therapies for heart failure. Iranian J. Pharmacol. Therap., 5: 87-94.
Direct Link  |  
Balakumar, P. and M. Singh, 2006. Possible role of caspase-3 in pathological and physiological cardiac hypertrophy in rats. Basic Clin. Pharmacol. Toxicol., 99: 418-424.
Direct Link  |  
Balakumar, P. and M. Singh, 2006. Possible role of poly (ADP-ribose) polymerase in pathological and physiological cardiac hypertrophy. Meth. Find. Exp. Clin. Pharmacol., 28: 683-689.
Direct Link  |  
Balakumar, P. and N. Mahadevan, 2011. Azilsartan: A novel angiotensin-II type 1 receptor blocker for treating hypertension. Int. J. Recent Adv. Pharm. Res., 2: 11-13.
Balakumar, P. and N. Mahadevan, 2011. Interplay between statins and PPARs in improving cardiovascular outcomes: A double-edged sword?. Br. J. Pharmacol., 10.1111/j.1476-5381.2011.01597.x.
CrossRef  |  
Balakumar, P. and N. Mahadevan, 2011. Multifaceted cardiac signal transduction mediated by G protein-coupled receptors: Potential target sites where an unambiguous attention is needed for exploring new drugs for cardiovascular disorders. Biomed. Aging Pathol., 10.1016/j.biomag.2011.04.004.
CrossRef  |  
Balakumar, P. and N.K. Sharma, 2011. Healing the diabetic heart: Does myocardial preconditioning work?. Cell. Signall., 10.1016/j.cellsig.2011.09.007.
CrossRef  |  
Balakumar, P. and S. Manjeet, 2006. Effect of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase in experimental cardiac hypertrophy. Int. J. Pharmacol., 2: 543-548.
CrossRef  |  Direct Link  |  
Balakumar, P., A. Rohilla and A. Thangathirupathi, 2010. Gentamicin-induced nephrotoxicity: Do we have a promising therapeutic approach to blunt it?. Pharmacol. Res., 62: 179-186.
PubMed  |  
Balakumar, P., A. Rohilla and M. Singh, 2008. Preconditioning and postconditioning to limit ischemia-reperfusion-induced myocardial injury: What could be the next footstep? Pharmacol. Res., 57: 403-412.
Balakumar, P., A. Rohilla, G. Singh, K. Singh and M. Singh, 2009. Modulation of cardioprotective effect of ischemic pre-and postconditioning in the hyperhomocysteinemic rat heart. Meth. Find. Exp. Clin. Pharmacol., 31: 71-79.
Balakumar, P., A. Rohilla, P. Krishan, P. Solairaj and A. Thangathirupathi, 2010. The multifaceted therapeutic potential of benfotiamine. Pharmacol. Res., 61: 482-488.
PubMed  |  
Balakumar, P., A.P. Singh and M. Singh, 2007. Appraisal of state-of-the-art rodent models of heart failure. J. Pharmacol. Toxicol. Meth., 56: 1-10.
CrossRef  |  
Balakumar, P., A.P. Singh, S.S. Ganti and M. Singh, 2007. Hyperhomocysteinemia and cardiovascular disorders: Is there a correlation? Trends Med. Res., 2: 160-166.
CrossRef  |  Direct Link  |  
Balakumar, P., A.P. Singh, S.S. Ganti, P. Krishan, S. Ramasamy and M. Singh, 2008. Resident cardiac mast cells: Are they the major culprit in the pathogenesis of cardiac hypertrophy?. Basic Clin. Pharmacol. Toxicol., 102: 5-9.
Direct Link  |  
Balakumar, P., B. Pateliya, G. Singh and M Singh, 2008. Pathophysiology of ischemia/reperfusion-induced myocardial injury: What we have learned from preconditioning and postconditioning? Iran. J. Pharmacol. Ther., 7: 115-122.
Direct Link  |  
Balakumar, P., H. Singh and M.B. Anand-Srivastava, 2009. Adenosine-A1 receptors activation restores the suppressed cardioprotective effects of ischemic preconditioning in hyperhomocysteinemic rat hearts. J. Cardiovasc. Pharmacol., 54: 204-212.
PubMed  |  
Balakumar, P., H. Singh, M. Singh and M.B. Anand-Srivastava, 2009. The impairment of preconditioning-mediated cardioprotection in pathological conditions. Pharmacol. Res., 60: 18-23.
PubMed  |  
Balakumar, P., J. Reddy and M. Singh, 2009. Do resident renal mast cells play a role in the pathogenesis of diabetic nephropathy? Mol. Cell. Biochem., 330: 187-192.
CrossRef  |  
Balakumar, P., M. Rose and M. Singh, 2007. Effect of fenofibrate in pressure overload-induced experimental cardiac hypertrophy. Int. J. Biol. Chem., 1: 104-110.
CrossRef  |  Direct Link  |  
Balakumar, P., M. Rose and M. Singh, 2007. PPAR ligands. Are they potential agents for cardiovascular disorders. Pharmacology, 80: 1-10.
CrossRef  |  Direct Link  |  
Balakumar, P., M. Rose and M. Singh, 2007. Peroxisome proliferator activated receptor agonists: Emerging therapy for cardiovascular complications. J. Pharmacol. Toxicol., 2: 205-219.
CrossRef  |  Direct Link  |  
Balakumar, P., M. Rose, S.S. Ganti, P. Krishan and M. Singh, 2007. PPAR dual agonists: Are they opening pandora's box?. Pharmacol. Res., 56: 91-98.
CrossRef  |  
Balakumar, P., M.K. Arora and M. Singh, 2009. Emerging role of PPAR ligands in the management of diabetic nephropathy. Pharmacol. Res., 60: 170-173.
CrossRef  |  
Balakumar, P., M.K. Arora, J. Reddy and M.B. Anand-Srivastava, 2009. Pathogenesis of diabetic nephropathy: Involvement of multifaceted signalling mechanism. J. Cardiovasc. Pharmacol., 54: 129-138.
Balakumar, P., N. Sharma, P. Krishan and N. Mahadevan, 2011. Linagliptin: A newly approved dipeptidyl peptidase-4 inhibitor for the management of type-2 diabetes mellitus. Int. J. Recent Adv. Pharm. Res., 3: 11-14.
Balakumar, P., N. Sharma, S. Kathuria, L. Babbar and N. Mahadevan, 2011. Perspectives in renin-angiotensin-aldosterone system blockade: What's new? Int. J. Recent Adv. Pharm. Res., 1: 1-7.
Balakumar, P., R. Sharma and M. Singh, 2008. Benfotiamine attenuates nicotine and uric acid-induced vascular endothelial dysfunction in the rat. Pharmacol. Res., 58: 356-363.
PubMed  |  
Balakumar, P., R. Sharma, A.N. Kalia and M. Singh, 2009. Hyperuricemia: Is it a risk factor for vascular endothelial dysfunction and associated cardiovascular disorders? Curr. Hypertens. Rev., 5: 1-6.
Direct Link  |  
Balakumar, P., R.U. Koladiya, S. Ramasamy, A. Rathinavel and M. Singh, 2008. Pharmacological interventions to prevent vascular endothelial dysfunction: Future directions. J. Health Sci., 54: 1-16.
Direct Link  |  
Balakumar, P., S. Jindal and M. Singh, 2007. Novel use of uric acid and sodium arsenite to induce vascular endothelial dysfunction in rats. J. Pharmacol. Toxicol., 2: 437-446.
CrossRef  |  Direct Link  |  
Balakumar, P., S. Jindal, D.I. Shah and M. Singh, 2007. Experimental models for vascular endothelial dysfunction. Trends Med. Res., 2: 12-20.
CrossRef  |  Direct Link  |  
Balakumar, P., S. Kathuria, G. Taneja, S. Kalra and N. Mahadevan, 2011. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?. J. Mol. Cell. Cardiol., .
PubMed  |  
Balakumar, P., S. Murthy and G. Jagadeesh, 2007. The basic concepts of scientific research and communication. Indian J. Pharmacol., 39: 303-306.
Balakumar, P., T. Kaur and M. Singh, 2008. Potential target sites to modulate vascular endothelial dysfunction: Current perspectives and future directions. Toxicology, 245: 49-64.
PubMed  |  
Balakumar, P., V.A. Chakkarwar and M. Singh, 2009. Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Mol. Cell. Bioch., 320: 149-162.
CrossRef  |  
Balakumar, P., V.A. Chakkarwar, P. Krishan and M. Singh, 2009. Vascular endothelial dysfunction: A tug of war in diabetic nephropathy? Biomed. Pharmacother., 63: 171-179.
PubMed  |  
Balakumar, P., V.A. Chakkarwar, V. Kumar, A. Jain, J. Reddy and M. Singh, 2008. Experimental models for nephropathy. J. Renin Angiotensin Aldosterone Syst., 9: 189-195.
CrossRef  |  
Bali, A., Y. Bansal, M. Sugumaran, J.S. Saggu and P. Balakumar et al., 2005. Design, synthesis, and evaluation of novelly substituted benzimidazole 14 compounds as angiotensin II receptor antagonists. Bioorg. Med. Chem. Lett., 15: 3962-3965.
CrossRef  |  Direct Link  |  
Jindal, S., M. Singh and P. Balakumar, 2008. Effect of bis (maltolato) oxovanadium (BMOV) in uric acid and sodium arsenite-induced vascular endothelial dysfunction in rats. Int. J. Cardiol., 128: 383-391.
Kalia, A.N., N. Mahadevan and P. Balakumar, 2008. Current trends in phytomedicine and challenges ahead. Indian J. Nat. Prod., 24: 38-40.
Kaur, J., K. Reddy and P. Balakumar, 2010. The novel role of fenofibrate in preventing nicotine and sodium arsenite-induced vascular endothelial dysfunction in the rat. Cardiovascular Toxicol., 10: 227-238.
PubMed  |  
Kaur, T., R.K. Goel and P. Balakumar, 2010. Effect of rosiglitazone in sodium arseniteinduced experimental vascular endothelial dysfunction. Arch. Pharm. Res., 33: 611-618.
CrossRef  |  
Kumar, V., S. Mukhopadhyay, P.S. Bedi, G. Singh and P. Balakumar, 2008. A novel modulatory role of vitamin D3 in exercise-induced apoptosis of rat skeletal muscle. Am. J. Food Technol., 3: 361-372.
CrossRef  |  Direct Link  |  
Rathinavel, A., G.S. Selvam, K. Ananthamurthy, M. Singh, P. Balakumar, S. Ramasamy and T. Ramprasath, 2007. Functional characterization of cardiac isoform of alpha 2 macroglobulin (CA2M): Identification of non-hypertrophic domain. Cardiology, 3: 20-23.
CrossRef  |  Direct Link  |  
Rohilla, A. and P. Balakumar, 2009. The infarct size-limiting effect of ischemic postconditioning (IPOC) is suppressed in isolated hyperhomocyteinemic rat hearts: The possible role of PKC-delta. Biomed. Pharmacother., 63: 787-791.
PubMed  |  
Rohilla, A., G. Singh, M. Singh and P. Balakumar, 2010. Possible involvement of PKC-delta in the abrogated cardioprotective potential of ischemic preconditioning in hyperhomocysteinemic rat hearts. Biomed. Pharmacother., 64: 195-202.
CrossRef  |  
Rose, M., P. Balakumar and M. Singh, 2007. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in Rats. Pharmacol., 80: 177-184.
Singh, A.P., M. Singh and P. Balakumar, 2008. Effect of mast cell stabilizers in hyperhomocysteinemia-induced cardiac hypertrophy in rats. J. Cardiovascular Pharmacol., 51: 596-604.
PubMed  |  
Singh, G., A. Rohilla, M. Singh and P. Balakumar, 2009. Possible role of JAK-2 in attenuated cardioprotective effect of ischemic preconditioning in hyperhomocysteinemic rat hearts. Yakugaku Zasshi, 129: 523-535.
CrossRef  |  PubMed  |  
Verma, S., K. Reddy and P. Balakumar, 2010. The defensive effect of benfotiamine in sodium arsenite-induced experimental vascular endothelial dysfunction. Biol. Trace Element Res., 137: 96-109.
CrossRef  |